Swing Therapeutics announced today the follow-up results from the PROSPER-FM study of Stanza, demonstrating the durability of the treatment for fibromyalgia symptoms out to 12 months.
The original study, published in The Lancet, validated Stanza’s digital behavioral treatment for fibromyalgia symptoms in the initial 12-week period. Building on these findings, the extension study evaluated the 12-month durability of symptom improvement with continued use of Stanza.
The study enrolled 60 participants who had completed the digital ACT arm of the original PROSPER-FM study, and who continued to use Stanza as needed. The results, presented this week at the annual meeting of the US Association for the Study of Pain, support the long-term benefits of the treatment:
- At 12 weeks, 80.0% of participants reported improvement in overall wellbeing (measured by Patient Global Impression of Change). This rate was sustained at 79.6% at the 12-month mark.
- Significant improvement from baseline on the Revised Fibromyalgia Impact Questionnaire (FIQ-R), a key measure of FM severity and function, was maintained over the entire 12 months.
- Additional benefits in pain intensity, pain interference, sleep interference, fatigue and sleep were durable for 12 months.
“We are incredibly encouraged by what these findings mean for the millions of fibromyalgia patients who are looking for meaningful, lasting change,” said Mike Rosenbluth, CEO of Swing.
If you or a loved one have fibromyalgia, learn more about Stanza and how to access treatment here.